DTU Publications (2000-2009)

2008

10-year follow-up of intensive glucose control in type 2 diabetes.

Holman RR. et al, (2008), N Engl J Med, 359, 1577 - 1589

Long-term follow-up after tight control of blood pressure in type 2 diabetes.

Holman RR. et al, (2008), N Engl J Med, 359, 1565 - 1576

Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.

Califf RM. et al, (2008), Am Heart J, 156, 623 - 632

Determining the most appropriate components for a composite clinical trial outcome.

Bethel MA. et al, (2008), Am Heart J, 156, 633 - 640

The impact of individualised cardiovascular disease (CVD) risk estimates and lifestyle advice on physical activity in individuals at high risk of CVD: a pilot 2 x 2 factorial understanding risk trial.

Price HC. et al, (2008), Cardiovasc Diabetol, 7

Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.

DREAM Trial Investigators . et al, (2008), Diabetes Care, 31, 1007 - 1014

Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).

Kahn SE. et al, (2008), Diabetes Care, 31, 845 - 851

Addition of insulin to oral therapy in type 2 diabetes - Reply

Holman RR. et al, (2008), NEW ENGLAND JOURNAL OF MEDICINE, 358, 1198 - 1198

Clinical decisions. Management of type 2 diabetes.

Goldberg RB. et al, (2008), N Engl J Med, 358, 293 - 297

Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Update regarding the thiazolidinediones.

Nathan DM. et al, (2008), Diabetologia, 51, 8 - 11

2007

Impact of the metabolic syndrome on macrovascular and microvascular outcomes in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study 78.

Cull CA. et al, (2007), Circulation, 116, 2119 - 2126

Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes.

Holman RR. et al, (2007), N Engl J Med, 357, 1716 - 1730

Stability of soluble adhesion molecules, selectins, and C-reactive protein at various temperatures: implications for epidemiological and large-scale clinical studies.

Hartweg J. et al, (2007), Clin Chem, 53, 1858 - 1860

GAD autoantibodies and epitope reactivities persist after diagnosis in latent autoimmune diabetes in adults but do not predict disease progression: UKPDS 77.

Desai M. et al, (2007), Diabetologia, 50, 2052 - 2060

Meta-analysis of the effects of n-3 polyunsaturated fatty acids on haematological and thrombogenic factors in type 2 diabetes.

Hartweg J. et al, (2007), Diabetologia, 50, 250 - 258

Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial.

Farmer A. et al, (2007), BMJ, 335

Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting.

Mount Hood 4 Modeling Group ., (2007), Diabetes Care, 30, 1638 - 1646

Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes.

Coleman RL. et al, (2007), Diabetes Care, 30, 1292 - 1293

An association analysis of the HLA gene region in latent autoimmune diabetes in adults.

Desai M. et al, (2007), Diabetologia, 50, 68 - 73

Metformin as first choice in oral diabetes treatment: the UKPDS experience.

Holman R., (2007), Journ Annu Diabetol Hotel Dieu, 13 - 20

2006

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

Kahn SE. et al, (2006), N Engl J Med, 355, 2427 - 2443

Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73.

Wright AD. et al, (2006), J Diabetes Complications, 20, 395 - 401

Assessing the impact of visual acuity on quality of life in individuals with type 2 diabetes using the short form-36.

Clarke PM. et al, (2006), Diabetes Care, 29, 1506 - 1511

Risk factors for renal dysfunction in type 2 diabetes: U.K. (vol 55, pg 1832, 2006)

Retnakaran R. et al, (2011), DIABETES, 60, 1823 - 1823

The variable number of tandem repeats upstream of the insulin gene is a susceptibility locus for latent autoimmune diabetes in adults.

Desai M. et al, (2006), Diabetes, 55, 1890 - 1894

Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective.

Holman RR., (2006), Metabolism, 55, S2 - S5

PROactive study.

Holman RR. et al, (2006), Lancet, 367, 25 - 26

Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75).

Stratton IM. et al, (2006), Diabetologia, 49, 1761 - 1769

A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe.

Viberti G. et al, (2006), Diabet Med, 23, 1289 - 1294

A clinical screening tool identifies autoimmune diabetes in adults: response to Fourlanos et al.

Davis TME. et al, (2006), Diabetes Care, 29

Effect of ramipril on the incidence of diabetes.

DREAM Trial Investigators . et al, (2006), N Engl J Med, 355, 1551 - 1562

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.

DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators . et al, (2006), Lancet, 368, 1096 - 1105

Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Nathan DM. et al, (2006), Diabetologia, 49, 1711 - 1721

Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes.

Kahn SE. et al, (2006), Diabetes, 55, 2357 - 2364

Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials.

Stettler C. et al, (2006), Am Heart J, 152, 27 - 38

2004

Changing aspirin use in patients with Type 2 diabetes in the UKPDS.

Cull CA. et al, (2004), Diabet Med, 21, 1368 - 1371

Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69.

Matthews DR. et al, (2004), Arch Ophthalmol, 122, 1631 - 1640

A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68).

Clarke PM. et al, (2004), Diabetologia, 47, 1747 - 1759

Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial.

Gerstein HC. et al, (2004), Diabetologia, 47, 1519 - 1527

A standardized triglyceride and carbohydrate challenge: the oral triglyceride tolerance test.

Mohanlal N. and Holman RR., (2004), Diabetes Care, 27, 89 - 94

A standardized triglyceride and carbohydrate challenge: response to Mohanlal and Holman.

Thanopoulou AC. et al, (2004), Diabetes Care, 27, 2092 - 2093

Comparative study of prognostic value for coronary disease risk between the U.K. Prospective diabetes study and framingham models: response to Protopsaltis et al.

Stevens RJ. and Holman R., (2004), Diabetes Care, 27, 1843 - 1844

Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66.

Stevens RJ. et al, (2004), Diabetes Care, 27, 201 - 207

2003

Poor pregnancy outcome for women with Type 2 diabetes.

Hadden DR. et al, (2003), Diabet Med, 20, 506 - 507

The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65).

Clarke P. et al, (2003), Diabet Med, 20, 442 - 450

Autoantibodies to the islet cell antigen SOX-13 are associated with duration but not type of diabetes.

Davis TME. et al, (2003), Diabet Med, 20, 198 - 204

Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

Adler AI. et al, (2003), Kidney Int, 63, 225 - 232

2002

Fire-and-forget in prevention of coronary heart disease.

Karpe F. and Holman R., (2002), Lancet, 360

UKPDS58--modeling glucose exposure as a risk factor for photocoagulation in type 2 diabetes.

Stevens RJ. et al, (2002), J Diabetes Complications, 16, 371 - 376

International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomized trial.

Molyneux A. et al, (2002), J Stroke Cerebrovasc Dis, 11, 304 - 314

International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: A randomised trial

Molyneux A. et al, (2002), Lancet, 360, 1267 - 1274

A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.

Viberti G. et al, (2002), Diabetes Care, 25, 1737 - 1743

Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis.

Homocysteine Studies Collaboration ., (2002), JAMA, 288, 2015 - 2022

Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: U.K. prospective diabetes study 61.

Colagiuri S. et al, (2002), Diabetes Care, 25, 1410 - 1417

Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62).

Clarke P. et al, (2002), Med Decis Making, 22, 340 - 349

UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine.

Kothari V. et al, (2002), Stroke, 33, 1776 - 1781

Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group IV: lifestyle and medical management of risk factors.

Grundy SM. et al, (2002), Circulation, 105, e153 - e158

A non-invasive frequent home blood glucose monitor

Lenzen H. et al, (2002), Practical Diabetes International, 19, 101 - 103

UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes.

Adler AI. et al, (2002), Diabetes Care, 25, 894 - 899

Human calcium/calmodulin-dependent protein kinase II gamma gene (CAMK2G): cloning, genomic structure and detection of variants in subjects with type II diabetes.

Gloyn AL. et al, (2002), Diabetologia, 45, 580 - 583

Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57).

Wright A. et al, (2002), Diabetes Care, 25, 330 - 336

Calculation of coronary risk in Type II diabetes: another cause for concern: authors' reply

Holman RR. et al, (2002), CLINICAL SCIENCE, 103, 219 - 219

2001

The UKPDS: implications for the dyslipidaemic patient.

Holman R., (2001), Acta Diabetol, 38 Suppl 1, S9 - 14

The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56).

Stevens RJ. et al, (2001), Clin Sci (Lond), 101, 671 - 679

Erratum: The UKPDS risk engine: A model for the risk of coronary heart disease in type II diabetes (UKPDS 56) (Clinical Science (2001) 101 (671-679))

Stevens RI. et al, (2002), Clinical Science, 102

Underestimation of the importance of homocysteine as a risk factor for cardiovascular disease in epidemiological studies.

Clarke R. et al, (2001), J Cardiovasc Risk, 8, 363 - 369

Butyrylcholinesterase K variant on chromosome 3 q is associated with Type II diabetes in white Caucasian subjects.

Hashim Y. et al, (2001), Diabetologia, 44, 2227 - 2230

Butyrylcholinesterase K variant on chromosome 3q is associated with Type II diabetes in white Caucasian subjects (vol 44, pg 2227, 2001)

Hashim Y. et al, (2002), DIABETOLOGIA, 45, 459 - 459

Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: U.K. Prospective Diabetes Study (UKPDS 55).

Davis TM. et al, (2001), Diabetes Care, 24, 1167 - 1174

An economic evaluation of atenolol vs. captopril in patients with Type 2 diabetes (UKPDS 54).

Gray A. et al, (2001), Diabet Med, 18, 438 - 444

Relationship between the severity of retinopathy and progression to photocoagulation in patients with Type 2 diabetes mellitus in the UKPDS (UKPDS 52).

Kohner EM. et al, (2001), Diabet Med, 18, 178 - 184

Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51).

Clarke P. et al, (2001), Diabetologia, 44, 298 - 304

UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis.

Stratton IM. et al, (2001), Diabetologia, 44, 156 - 163

2000

Possible prevention of type 2 diabetes with acarbose or metformin over three years

Citroën HA. et al, (2000), DIABETOLOGIA, 43, A73 - A73

Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration.

Neal B. et al, (2000), Lancet, 356, 1955 - 1964

Life-expectancy projection by modelling and computer simulation (UKPDS 46).

Stevens R. et al, (2000), Diabetes Res Clin Pract, 50 Suppl 3, S5 - 13

Seeing what you want to see in randomised controlled trials. Authors' choice of study was ill informed.

Holman R., (2000), BMJ, 321, 1078 - 1079

Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study.

Adler AI. et al, (2000), BMJ, 321, 412 - 419

Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study

(2001), BMJ (Clinical research ed.), 322, 90 - 90

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.

Stratton IM. et al, (2000), BMJ, 321, 405 - 412

Effects of three months' diet after diagnosis of Type 2 diabetes on plasma lipids and lipoproteins (UKPDS 45)

Manley SE. et al, (2000), Diabetic Medicine, 17, 518 - 523

Does the choice of treatment for type 2 diabetes affect the physiological response to hypoglycemia?

Peacey SR. et al, (2000), Diabetes Care, 23, 1022 - 1023

Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group.

Gray A. et al, (2000), BMJ, 320, 1373 - 1378

PAST PUBLICATIONS

Cookies on this website